IMMU Immunomedics, Inc.

7.72
+0.25  (3%)
Previous Close 7.47
Open 7.68
Price To book 0.00
Market Cap 846.14M
Shares 109,604,000
Volume 6,442,221
Short Ratio 6.03
Av. Daily Volume 3,399,540

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment due to commence late 2017. BLA filing due between late 4Q 2017 and 1Q 2018. Phase 2 data to be used for accelerated approval.
SACTUZUMAB GOVITECAN (IMMU-132)
Cancer - metastatic triple-negative breast cancer
Phase 2 update provided at ASCO June 2016. Ongoing through 2017.
SACITUZUMAB GOVITECAN
Non-small cell lung cancer (NSCLC)
Phase 2 interim data presented April 2016
Labetuzumab govitecan
Metastatic colorectal cancer (mCRC)
Phase 3 trial terminated due to poor efficacy
Clivatuzumab tetraxetan
Cancer - Pancreatic
Endpoints not met July 2015
Epratuzumab (EMBODY 1 and 2)
Lupus

Latest News

  1. Biotech Movers: Immunomedics, Aerie, Exelixis
  2. ETFs with exposure to Immunomedics, Inc. : May 25, 2017
  3. Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017
  4. Edited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT
  5. Immunomedics reports 3Q loss
  6. Immunomedics Announces Third Quarter Fiscal 2017 Results and Clinical Program Developments
  7. Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2017 Results
  8. The Head-Scratching Reason Immunomedics Rose by as Much as 12%
  9. Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : May 8, 2017
  10. Today's Research Report on Biotech Stocks to Watch: Immunomedics and Esperion Therapeutics
  11. Immunomedics Breaks Out, But Will It Last?
  12. Did Immunomedics Rise Too Much as Seattle Genetics Deal Terminated?
  13. Immunomedics, Seattle Genetics Scrap License Deal
  14. Why Immunomedics, MercadoLibre, and Pearson Jumped Today
  15. Why Immunomedics, Inc. Rocketed Today
  16. Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated
  17. Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value
  18. Immunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : April 25, 2017
  19. Immunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : April 24, 2017
  20. Why Immunomedics, Inc. Got Hammered Today